Oxford BioMedica (OXB) Share Forecast & Price Target

Compare

102 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OXB Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Oxford

BioMedica

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OXB Stock 12 Month Forecast

Average Price Target

685.90p

▲(19.29% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Oxford BioMedica in the last 3 months. The average price target is 685.90p with a high forecast of 969.82p and a low forecast of 451.29p. The average price target represents a 19.29% change from the last price of 575.00p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"290":"290p","460":"460p","630":"630p","800":"800p","970":"970p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":969.82050748,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">969.82p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":685.89770868,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">685.90p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":451.28781704,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">451.29p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[290,460,630,800,970],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,618,645.06311596,672.12623192,699.18934788,726.25246384,753.3155798,780.37869576,807.44181172,834.50492768,861.56804364,888.6311596,915.69427556,942.7573915199999,{"y":969.82050748,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,618,623.2229006676923,628.4458013353847,633.668702003077,638.8916026707692,644.1145033384615,649.3374040061539,654.5603046738462,659.7832053415385,665.0061060092308,670.2290066769231,675.4519073446154,680.6748080123077,{"y":685.89770868,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,618,605.1759859261539,592.3519718523077,579.5279577784615,566.7039437046154,553.8799296307692,541.0559155569231,528.231901483077,515.4078874092307,502.5838733353846,489.75985926153845,476.9358451876923,464.11183111384616,{"y":451.28781704,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":372,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":381.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":405,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":295,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":464.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":569,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":590,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":618,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target969.82p

Average Price Target685.90p

Lowest Price Target451.29p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kane Slutzkin

Deutsche Bank

380p→735p

Buy

27.83%

Upside

Upgraded

12/18/25

Oxford Biomedica upgraded to Buy from Hold at Deutsche BankOxford Biomedica upgraded to Buy from Hold at Deutsche Bank

Zain Ebrahim

J.P. Morgan

400p→550p

Hold

-4.35%

Downside

Reiterated

12/08/25

Oxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorganOxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorgan

James Orsborne

Stifel Nicolaus

725p

Buy

26.09%

Upside

Reiterated

10/22/25

Oxford BioMedica: Strategic Positioning and Growth Potential in Cell and Gene Therapy

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

451p

Buy

-21.57%

Downside

Reiterated

10/07/25

Oxford BioMedica (OXBDF) Receives a Buy from Canaccord Genuity

Charles Weston

RBC Capital

930p→970p

Buy

68.70%

Upside

Reiterated

10/06/25

RBC Capital Sticks to Its Buy Rating for Oxford BioMedica (OXBDF)

James Vane

Jefferies

566p→687p

Buy

19.48%

Upside

Reiterated

09/03/25

Jefferies Sticks to Their Buy Rating for Oxford BioMedica (OXBDF)

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

451p

Buy

-21.57%

Downside

Reiterated

08/01/25

Peel Hunt Keeps Their Buy Rating on Oxford BioMedica (OXBDF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kane Slutzkin

Deutsche Bank

380p→735p

Buy

27.83%

Upside

Upgraded

12/18/25

Oxford Biomedica upgraded to Buy from Hold at Deutsche BankOxford Biomedica upgraded to Buy from Hold at Deutsche Bank

Zain Ebrahim

J.P. Morgan

400p→550p

Hold

-4.35%

Downside

Reiterated

12/08/25

Oxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorganOxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorgan

James Orsborne

Stifel Nicolaus

725p

Buy

26.09%

Upside

Reiterated

10/22/25

Oxford BioMedica: Strategic Positioning and Growth Potential in Cell and Gene Therapy

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

451p

Buy

-21.57%

Downside

Reiterated

10/07/25

Oxford BioMedica (OXBDF) Receives a Buy from Canaccord Genuity

Charles Weston

RBC Capital

930p→970p

Buy

68.70%

Upside

Reiterated

10/06/25

RBC Capital Sticks to Its Buy Rating for Oxford BioMedica (OXBDF)

James Vane

Jefferies

566p→687p

Buy

19.48%

Upside

Reiterated

09/03/25

Jefferies Sticks to Their Buy Rating for Oxford BioMedica (OXBDF)

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

451p

Buy

-21.57%

Downside

Reiterated

08/01/25

Peel Hunt Keeps Their Buy Rating on Oxford BioMedica (OXBDF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oxford BioMedica

1 Month

xxx

Success Rate

11/24 ratings generated profit

Average Return

+2.80%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 45.83% of your transactions generating a profit, with an average return of +2.80% per trade.

3 Months

xxx

Success Rate

5/7 ratings generated profit

Average Return

+16.04%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +16.04% per trade.

1 Year

James OrsborneStifel Nicolaus

Success Rate

7/7 ratings generated profit

Average Return

+62.09%

reiterated a buy rating 2 months ago

Copying James Orsborne's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +62.09% per trade.

2 Years

xxx

Success Rate

7/7 ratings generated profit

Average Return

+89.36%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +89.36% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OXB Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OXB has received 5 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. OXB average Analyst price target in the past 3 months is 685.90.

Each month's total comprises the sum of three months' worth of ratings.

OXB Financial Forecast

OXB Earnings Forecast

Next quarter’s earnings estimate for OXB is -0.24p with a range of -0.28p to -0.20p. The previous quarter’s EPS was -0.08p. OXB beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year OXB has Performed in-line its overall industry.

OXB Sales Forecast

Next quarter’s sales forecast for OXB is 72.65M with a range of 72.30M to 73.00M. The previous quarter’s sales results were 77.99M. OXB beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year OXB has Outperformed its overall industry.

OXB Stock Forecast FAQ

What is GB:OXB’s average 12-month price target, according to analysts?

Based on analyst ratings, Oxford Biomedica (otc)’s 12-month average price target is 685.90.

What is GB:OXB’s upside potential, based on the analysts’ average price target?

Oxford Biomedica (otc) has 19.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Oxford Biomedica (otc) a Buy, Sell or Hold?

Oxford Biomedica (otc) has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Oxford Biomedica (otc)’s share price target?

The average share price target for Oxford Biomedica (otc) is 685.90. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 969.82p ,and the lowest forecast is 451.29p. The average share price target represents 19.29% Increase from the current price of 575p.

What do analysts say about Oxford Biomedica (otc)?

Oxford Biomedica (otc)’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Oxford Biomedica (otc)?

To buy shares of GB:OXB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Oxford BioMedica (OXB) Share Forecast & Price Target

OXB Analyst Ratings

OXB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Oxford BioMedica

OXB Analyst Recommendation Trends

OXB Financial Forecast

OXB Earnings Forecast

OXB Sales Forecast

OXB Stock Forecast FAQ

Detailed List of Analyst Forecasts